Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 9/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896631 | 0.90 | PTGS2 (0.36) | MEN1RAB9AKMT2ACACNA2D1KDM4E | |
| SCHEMBL1869939 | 0.83 | RAB9A (0.36) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL896518 | 0.81 | KMT2A (0.38) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL896318 | 0.81 | CNR2 (0.37) | MEN1RAB9AKMT2ACACNA2D1KDM4E | |
| SCHEMBL10000738 | 0.80 | CNR2 (0.35) | GABRG2GABRB3GABRA5GABRA3MEN1 | |
| SCHEMBL2356139 | 0.80 | MEN1 (0.36) | MEN1RAB9AKMT2AMAPT | |
| SCHEMBL2350657 | 0.80 | RAB9A (0.38) | GABRG2GABRB3GABRA5GABRA3MEN1 | |
| SCHEMBL2351120 | 0.78 | MEN1 (0.34) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL3971627 | 0.78 | RAB9A (0.39) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2348149 | 0.78 | RAB9A (0.38) | MEN1RAB9AKMT2AKDM4EGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598176-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
| EP-1958946-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1958946-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | PLPBP, PNPO, PDXK | GABRG2 3604/4885GABRB3 4233/4885GABRA5 1781/4885 |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | PLPBP, PNPO, PDXK | GABRG2 3604/4885GABRB3 4233/4885GABRA5 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.